Drug Search Results
More Filters [+]

Flutafuranol (18f)

Alternative Names: flutafuranol (18f), NAV-4694, NAV4694, NAV 4694, flutafuranol
Latest Update: 2024-10-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Navidea
Company Location: DUBLIN OH 43017
Company CEO: Michael S. Rosol
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Flutafuranol (18f)

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Alzheimer Disease

Phase 2: Alzheimer Disease|Cognitive Dysfunction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

APEX

N/A

Enrolling by invitation

Alzheimer Disease

2028-06-01

ADNI4

N/A

Recruiting

Cognitive Dysfunction|Alzheimer Disease

2027-07-31

HEAD

P1

Recruiting

Alzheimer Disease

2027-05-31

ADiOSA

N/A

Terminated

Alzheimer Disease|Dementia, Vascular|Acute Respiratory Distress Syndrome|Conduct Disorder

2019-12-12

Recent News Events